Protalix BioTherapeutics, Inc. (PLX) stock
PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3047% below fair value
$3.02+0.14 (+4.86%)
Close on Nov 18, 2026Market cap $243.33MP/E 13.1Yield –
Protalix BioTherapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Protalix BioTherapeutics's free cash flow for the twelve months ending Jun 30, 2026 was $7.67M. For fiscal 2025 it was -$13.63M, down 284.4% from the year before. The highest annual figure on record is $38.26M in fiscal 2009.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$13.63M | -284.4% |
| FY2024 | Dec 31, 2024 | $7.39M | – |
| FY2023 | Dec 31, 2023 | -$2.47M | – |
| FY2022 | Dec 31, 2022 | -$25.63M | – |
| FY2021 | Dec 31, 2021 | -$11.74M | – |
| FY2020 | Dec 31, 2020 | -$26.76M | – |
| FY2019 | Dec 31, 2019 | -$19.99M | – |
| FY2018 | Dec 31, 2018 | -$8.43M | – |
| FY2017 | Dec 31, 2017 | -$10.97M | – |
| FY2016 | Dec 31, 2016 | -$32.95M | – |
| FY2015 | Dec 31, 2015 | -$24.75M | – |
| FY2014 | Dec 31, 2014 | -$30.07M | – |
| FY2013 | Dec 31, 2013 | -$32.54M | – |
| FY2012 | Dec 31, 2012 | -$1.43M | – |
| FY2011 | Dec 31, 2011 | -$29.28M | – |
| FY2010 | Dec 31, 2010 | -$46.32M | -221.1% |
| FY2009 | Dec 31, 2009 | $38.26M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$10.99M | – |
| Q1 FY2026 | Mar 31, 2026 | $21.26M | – |
| Q4 FY2025 | Dec 31, 2025 | $1.63M | -54.4% |
| Q3 FY2025 | Sep 30, 2025 | -$4.23M | -205.3% |
| Q2 FY2025 | Jun 30, 2025 | -$5.66M | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.36M | -249.4% |
| Q4 FY2024 | Dec 31, 2024 | $3.57M | +6.6% |
| Q3 FY2024 | Sep 30, 2024 | $4.02M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.78M | -179.3% |
| Q1 FY2024 | Mar 31, 2024 | $3.59M | – |
| Q4 FY2023 | Dec 31, 2023 | $3.35M | – |
| Q3 FY2023 | Sep 30, 2023 | -$7.34M | – |
| Q2 FY2023 | Jun 30, 2023 | $4.77M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.25M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.82M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.26M | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.48M | -220.0% |
| Q1 FY2022 | Mar 31, 2022 | -$6.06M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.54M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.22M | – |
| Q2 FY2021 | Jun 30, 2021 | $6.24M | – |
| Q1 FY2021 | Mar 31, 2021 | -$10.22M | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.83M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.18M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.72M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.62M | -126.7% |
| Q2 FY2019 | Jun 30, 2019 | -$5.21M | – |
| Q1 FY2019 | Mar 31, 2019 | -$7.45M | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.19M | -124.2% |
| Q3 FY2018 | Sep 30, 2018 | $13.54M | – |
| Q2 FY2018 | Jun 30, 2018 | -$8.11M | – |
| Q1 FY2018 | Mar 31, 2018 | -$9.66M | – |
| Q4 FY2017 | Dec 31, 2017 | $17.30M | – |
| Q3 FY2017 | Sep 30, 2017 | -$10.68M | – |
| Q2 FY2017 | Jun 30, 2017 | -$8.94M | – |
| Q1 FY2017 | Mar 31, 2017 | -$8.65M | – |
| Q4 FY2016 | Dec 31, 2016 | -$7.46M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.60M | – |
| Q2 FY2016 | Jun 30, 2016 | -$12.02M | – |
See a number that looks wrong?